ClinicalTrials.gg
CompletedNCT04990414Updated Aug 4, 2021

Cognitive Behaviour Therapy for Voices and Dissociation

A Phase 2 interventional study of Cognitive Behavioural Therapy in Schizophrenia, Psychological Trauma and Dissociation, sponsored by Greater Manchester Mental Health NHS Foundation Trust. Completed. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2021-08-04.

Sponsored by Greater Manchester Mental Health NHS Foundation Trust · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 7 years 7 months after the study started (first participant enrolled Nov 2013, registered Jun 2021).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
19
Allocation
Not applicable
Ages
16 Years and older
Sex
All
01

Study summary

Case series design with participants with psychosis with a history of interpersonal trauma/abuse and current distressing auditory verbal hallucinations and dissociative experience. Participants were offered up to 24 therapy sessions over a 6-month intervention window.

Read the detailed description

Objectives: Previous studies have suggested that dissociation might represent an important mechanism in the maintenance of auditory verbal hallucinations (i.e., voices) in people who have a history of traumatic life experiences. This study investigated whether a cognitive behavioural therapy (CBT) intervention for psychosis augmented with techniques specifically targeting dissociative symptoms could improve both dissociation and auditory hallucination severity in a sample of voice hearers with psychosis and a history of interpersonal trauma (e.g., exposure to sexual, physical, and/or emotional abuse).

Design: Case series.

Methods: A total of 19 service users with psychosis were offered up to 24 therapy sessions over a 6-month intervention window. Participants were assessed four times over a 12-month period using measures of dissociation, psychotic symptoms severity, and additional secondary mental-health and recovery measures.

02

Conditions studied

  • Schizophrenia
  • Psychological Trauma
  • Dissociation
  • Hallucinations
03

In context

Schizophrenia

3,574 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

This study's enrollment of 19 is below the median of 70 across 2,952 interventional studies indexed under Schizophrenia.

Browse Schizophrenia studies →

Lead sponsor

Greater Manchester Mental Health NHS Foundation Trust is the lead sponsor of 7 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Be in contact with mental health services.
  2. Have an identified care coordinator.
  3. Meet ICD-10 criteria for schizophrenia, schizoaffective disorder or delusional disorder or meet entry criteria for an Early Intervention in Psychosis service in order to allow for diagnostic uncertainty in early phases of psychosis.
  4. History of voice-hearing for a minimum of six months.
  5. Aged 16 and above.
  6. Score ≥ 2 (i.e. "Voices occurring at least once a day") on the frequency item of the PSYRATS.
  7. Score ≥ 3 (i.e. "Voices are very distressing, although subject could feel worse") on the distress intensity rating of the PSYRATS.
  8. Confirmed that they consider AVHs, dissociative experiences, and/or trauma as their main problem or presenting difficulty, and that would like to receive a psychological intervention specifically designed to address these difficulties - this will be assessed using four items integrated in the PSYRATS interview administered as part of the present study, and the self-reported therapy goals generated through the CHOICE short form.
  9. Score ≥ 1 on any of the items of the Bref Betrayal Trauma Survey assessing lifetime exposure to interpersonal trauma (i.e. items 3-11).
  10. scores suggestive of clinical levels of dissociative symptoms, as indicated by a score > 20 on the Dissociative Experiences Scale, time bound
  11. Capacity to provide .
  12. Judged by their clinician to be clinically stable for the preceding 4 weeks

Exclusion criteria

Exclusion Criteria:

  1. Any person without capacity to provide written .
  2. If the experience of voices/psychosis is organic in origin (for example, hallucinatory experiences linked to traumatic brain injuries, organic psychoses, or emerging in the context of dementing conditions).
  3. Insufficient command of English to complete the research interviews and measures.
  4. Intellectual disability, or severe cognitive dysfunction that might preclude the individual's ability to provide informed consent, understand the study procedure and/or fully appreciate the potential consequences of their participation.
  5. Primary diagnosis of substance misuse dependency.
  6. Where care coordinators identify reasons for why participation might be potentially detrimental.
  7. Inpatient/acute care needed.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
19 participants (actual)

Study arms

  • Experimental
    CBT for voices and dissociation

    24 sessions of Cognitive Behavioural Therapy (CBT) over a 6-month period treatment window.

    Other: Cognitive Behavioural Therapy

Interventions

  • OtherCognitive Behavioural Therapy

    Sessions 1-4 were focused on engagement, assessment of presenting problems, identification of treatment goals and normalization/ psychoeducation. Sessions 5- 14, focused on techniques to manage dissociative responses and/or increase perceived controllability of dissociation. Although further work on dissociation and/or trauma was encouraged, the targets for intervention in subsequent sessions (15-22) and the strategies selected depended on individual formulation of clients' difficulties and negotiation with the client. This could include re-appraisals on negative beliefs about dissociative experiences, cognitive and/or behavioural change strategies targeting core appraisals of voices leading to related distress, trauma-related techniques (e.g., imagery techniques,), or consolidation of a developmental/longitudinal psychological formulation of the client's difficulties. The final two sessions focused on plans for relapse prevention and maintenance of gains.

06

What researchers measure

Primary outcomes

  1. Change in the Dissociative Experiences Scale - time bound

    Change in the frequency of dissociative experiences, assessed via a questionnaire measure assessing presence and frequency of dissociative experiences in the previous month

    Time frame: baseline, at mid-treatment (approximately 3 months after the baseline assessment), at the end of treatment (6 months after baseline), and again at 6 months following the end of treatment

  2. Change in the Psychotic Symptoms Rating Scale - auditory hallucinations subscale

    change in the severity of hallucinatory experiences, assessed via a clinical interview measuring for presence and severity of auditory hallucinations in the previous week

    Time frame: baseline, at mid-treatment (approximately 3 months after the baseline assessment), at the end of treatment (6 months after baseline), and again at 6 months following the end of treatment

Secondary outcomes

  1. Change in the Psychotic Symptoms Rating Scale - delusions subscale

    change in the severity of delusional beliefs, assessed via a clinical interview measuring for presence and severity of delusions in the previous week

    Time frame: baseline, at mid-treatment (approximately 3 months after the baseline assessment), at the end of treatment (6 months after baseline), and again at 6 months following the end of treatment

  2. Change in the Impact of Events Scale Revised

    change in the severity of post-traumatic symptoms, assessed via a questionnaire measuring arousal, hypervigilance, and intrusions in the previous week

    Time frame: baseline, at mid-treatment (approximately 3 months after the baseline assessment), at the end of treatment (6 months after baseline), and again at 6 months following the end of treatment

  3. Change in the short Depression, Anxiety and Stress Scales

    change in the severity of emotional distress, assessed via a questionnaire measuring symptoms of anxiety, depression, and stress in the previous week

    Time frame: baseline, at mid-treatment (approximately 3 months after the baseline assessment), at the end of treatment (6 months after baseline), and again at 6 months following the end of treatment

  4. Change in the Questionnaire about the Process of Recovery

    change in subjective recovery from psychosis, assed via a self-report questionnaire measuring perceived recovery from psychosis-related difficulties

    Time frame: baseline, at mid-treatment (approximately 3 months after the baseline assessment), at the end of treatment (6 months after baseline), and again at 6 months following the end of treatment

  5. Change in the short-form of the CHoice of Outcome In Cbt for psychosEs (CHOICE)

    change in service user-led outcome measure, assessed using a validated questionnaire developed to evaluate outcomes of cognitive behavioural interventions for psychosis

    Time frame: baseline, at mid-treatment (approximately 3 months after the baseline assessment), at the end of treatment (6 months after baseline), and again at 6 months following the end of treatment

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Varese F, Douglas M, Dudley R, Bowe S, Christodoulides T, Common S, Grace T, Lumley V, McCartney L, Pace S, Reeves T, Morrison AP, Turkington D. Targeting dissociation using cognitive behavioural therapy in voice hearers with psychosis and a history of interpersonal trauma: A case series. Psychol Psychother. 2021 Jun;94(2):247-265. doi: 10.1111/papt.12304. Epub 2020 Sep 10. PubMed 32914542 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2013 to primary completion in Jan 2019, 62 months.

Of 44 non-industry phase 2 interventional studies under Schizophrenia, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 73. This study's 62 months is above that.

Counting every sponsor, half of 101 studies reached it within 25 months; a quarter within 15 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 24, 2021
First posted
Aug 4, 2021
StartActual
Nov 24, 2013
Primary completionActual
Jan 29, 2019
CompletionActual
Jan 29, 2019
Last update
Aug 4, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 4, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04990414
Lead sponsor
Greater Manchester Mental Health NHS Foundation Trust
Responsible party
Filippo Varese (Senior Clinical Lecturer, University of Manchester) — Principal investigator
First posted
Aug 4, 2021
Start date
Nov 24, 2013
Primary completion
Jan 29, 2019
Completion
Jan 29, 2019
Last update
Aug 4, 2021

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion